News

A shift toward real infrastructure: clinical stacks, publishable decoding results, and device platforms built for trials.

Early February’s strongest implantable-BCI signals were clinical repeatability and design-for-chronicity: second-in-human execution, insertion mechanics, and flexible-material evidence.

Late January was about scaling implant trials, new noninvasive ultrasound bets, tooling/dev workflows, and the messy ethics of long-term support.

The year opened with scale/automation talk for implants, China laying standards groundwork, and CES pushing ‘BCI-adjacent’ consumer neurotech into view.